Majumder et al. conducted a meta-analysis suggesting that CSF TDP-43 levels could be a promising biomarker in FTD-ALS spectrum disorders in particular ALS patients (10). This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.